Genmab A/S (GMAB) Reports Q1 Net Sales of DARZALEX of $1.86B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022
April 19, 2022 6:29 AM EDTCompany Announcement
Net sales of DARZALEX® in the first quarter of 2022 totaled USD 1,856 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc.COPENHAGEN, Denmark; April 19, 2022... More
